Common VWF Exon 28 Polymorphisms in African Americans Affecting the VWF Activity Assay by Ristocetin Cofactor.
Gain-of-function GPlb ELISA Assay for VWF Activity in the Zimmermann Program for the Molecular and Clincal Biology of VWF.
Absent Collagen Binding in a VWF A3 Domain Mutant: Utility of the VWF:CB in Diagnosis of VWD.
Journal of Thrombosis and Haemostasis
Limitations of the Ristocetin Cofactor Assay in Measurement of von Willebrand Factor Function.
Journal of Thrombosis and Haemostasis
Characterization of zebrafish von Willebrand factor reveals conservation of domain structure, multimerization, and intracellular storage.
Adv Hematol., 2012:214209 (2012)
Factor VIII inhibitors: von willebrand factor makes a difference in vitro and in vivo.
J. Thromb. Haemost., Aug (2012)
Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis.
J. Thromb. Haemost., Aug;10(8):1646-52 (2012)
Lentivirus-mediated platelet gene therapy of murine hemophiliaÂ A with pre-existing anti-factorÂ VIII immunity.
J. Thromb. Haemost., Aug;10(8):1570-80 (2012)
Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.
J. Thromb. Haemost., Jul;10(7):1425-32 (2012)
Critical von Willebrand factor A1 domain residues influence type VI collagen binding.
J. Thromb. Haemost., Jul;10(7):1417-24 (2012)
von Willebrand factor (VWF) propeptide binding to VWF D'D3 domain attenuates platelet activation and adhesion.
Blood., May;119(20):4769-78 (2012)
Platelet and endothelial expression of clotting factors for the treatment of hemophilia.
Thromb. Res., May;129 Suppl 2:S46-8 (2012)
Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice.
Haemophilia., Jul;18(4):639-46 (2012)
VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.
Blood., Mar;119(9):2135-40 (2012)
Von Willebrand disease in the United States: a perspective from Wisconsin.
Semin. Thromb. Hemost., Jul;37(5):528-34 (2011)
Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy.
Mol. Ther., Mar;20(3):625-32 (2012)
Alternative strategies for gene therapy of hemophilia.
Hematology Am Soc Hematol Educ Program., 2010:197-202 (2010)
Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
Blood., Feb;117(6):e67-74 (2011)
Platelets as delivery systems for disease treatments.
Adv. Drug Deliv. Rev., Sep;62(12):1196-203 (2010)
Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.
Blood., Oct;116(16):3049-57 (2010)
Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice.
Blood., Aug;116(8):1235-43 (2010)
Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
Blood., Jul;116(2):280-6 (2010)
Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.
J. Thromb. Haemost., Nov;7(11):1832-9 (2009)
Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site.
Blood., Aug;114(8):1666-74 (2009)
Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.
Am. J. Hematol., Jun;84(6):366-70 (2009)
Genetic alteration of the D2 domain abolishes von Willebrand factor multimerization and trafficking into storage.
J. Thromb. Haemost., Apr;7(4):641-50 (2009)
At least type VWD2B is a discrete variant of VWD, isn't it?
Blood., Jan;113(3):501 (2009)
Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.
J. Pediatr. Hematol. Oncol., Sep;30(9):708-11 (2008)
Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Blood., Oct;112(7):2713-21 (2008)
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Blood., May;111(10):4979-85 (2008)
Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A.
J. Thromb. Haemost., Feb;5(2):352-61 (2007)
Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
Blood., Nov;108(10):3344-51 (2006)
Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
J. Clin. Invest., Jul;116(7):1974-82 (2006)
Regulated release of VWF and FVIII and the biologic implications.
Pediatr Blood Cancer., May;46(5):547-53 (2006)
von Willebrand disease--the relevance of history.
J. Thromb. Haemost., Dec;3(12):2617-8 (2005)
Genetic mutations in von Willebrand disease identified by DHPLC and DNA sequence analysis.
Mol. Genet. Metab., Mar;87(3):262-71 (2006)
von Willebrand factor: the new treatment paradigm--introduction.
Blood Coagul. Fibrinolysis., Apr;16 Suppl 1:S1-2 (2005)
Intracellular interaction of von Willebrand factor and factor VIII depends on cellular context: lessons from platelet-expressed factor VIII.
Blood., Jun;105(12):4674-6 (2005)
Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX.
J. Thromb. Haemost., Nov;2(11):1989-97 (2004)
Re-establishment of VWF-dependent Weibel-Palade bodies in VWD endothelial cells.
Blood., Jan;105(1):145-52 (2005)
Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII.
J. Thromb. Haemost., Dec;1(12):2477-89 (2003)
Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF.
Mol. Genet. Metab., May;79(1):25-33 (2003)
von Willebrand disease: a common pediatric disorder.
Pediatr Ann., Sep;30(9):534-40 (2001)
Naturally occurring mutations in glycoprotein Ibalpha that result in defective ligand binding and synthesis of a truncated protein.
Blood., Jul;92(1):175-83 (1998)
Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin.
Blood., Jun;87(11):4879-86 (1996)
Therapy of von Willebrand disease.
Semin. Thromb. Hemost., 19(1):37-47 (1993)
Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor-dependent agglutination of platelets.
J. Biol. Chem., May;266(13):8149-55 (1991)
Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products.
J. Lab. Clin. Med., Oct;116(4):439-47 (1990)
Report on the diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the ICTH-Subcommittee on Protein C and Protein S.
Thromb. Haemost., Jun;61(3):529-31 (1989)
Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis.
J. Pediatr., Apr;114(4 Pt 1):528-34 (1989)
Homozygous protein C deficiency: observations on the nature of the molecular abnormality and the effectiveness of warfarin therapy.
Pediatrics., Feb;81(2):272-6 (1988)